NL-OMON46307已完成3 期
A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab Versus Standard of Care Platinum-Based Chemotherapy as First Line Treatment in Patients with PD-L1-High Expression Advanced Non Small-Cell Lung Cancer (NSCLC) - China PEAR
Astra Zeneca0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Histologically or cytologically documented Stage IV NSCLC (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology; IASLC Staging Manual in Thoracic Oncology);- Patients must have tumors that lack sensitizing EGFR mutation (e.g., exon 19 deletion or exon 21 L858R, exon 21 L861Q, exon 18 G719X, or exon 20 S7681 mutation) and ALK rearrangement;- Patient must have tumor cell PD-L1-high expression status, prior to randomization, defined as *25% PD-L1*membrane expression in tumoral tissue with the Ventana SP263 PD-L1 IHC assay determined by a reference laboratory;- World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrolment;- At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as *10 mm in the longest diameter (except lymph nodes which must have a short axis *15 mm) with CT or MRI and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines;- Must have a life expectancy of at least 12 weeks
排除标准
- •- Prior chemotherapy or any other systemic therapy for advanced NSCLC. ;- Prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines;- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug;- Brain metastases or spinal cord compression unless the patient is stable (asymptomatic, no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to start of study treatment;- History of leptomeningeal carcinomatosis;- Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant;- Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment. The following are exceptions to this criterion: Patients with vitiligo or alopecia, Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment, Any chronic skin condition that does not require systemic therapy, Patients without active disease in the last 5 years may be included but only after consultation with the study physician, Patients with celiac disease controlled by diet alone;- History of active primary immunodeficiency;- Active infection, including tuberculosis (clinical evaluation), hepatitis B, hepatitis C, or human immunodeficiency virus (HIV, positive HIV 1 or 2 antibodies);- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
- •Intranasal, inhaled, topical steroids, or local steroid injections (eg., intra-articular injection).
- •Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
- •Steroids as premedication for hypersensitivity reactions (eg., CT scan premedication);- Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP.;- Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP;- History of allogenic organ transplantation;- History of another primary malignancy except for:
- •Malignancy treated with curative intent and with no known active disease * 5 years before the first dose of study drug and of low potential risk for recurrence
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ);- Medical contraindication to platinum (cisplatin or carboplatin)-based doublet chemotherapy.;- Positive urinary or serum pregnancy test for female pre-menopausal patients;- Female patients who are pregnant or breast-feeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 90 days after the last dose of durvalumab.;- Known allergy or hypersensitivity to IP or any excipient or to other humanized mAbs
研究者
相似试验
进行中（未招募）
1 期
A study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung CancerFirst line patients with Advanced Non Small-Cell Lung Cancer (NSCLC) with PD-L1 positive membrane expression in tumoral tissue and lacking activating epdermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) infusions.MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2018-001375-21-NLAstraZeneca AB650
进行中（未招募）
1 期
A study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung CancerFirst line patients with Advanced Non Small-Cell Lung Cancer (NSCLC) with PD-L1 high membrane expression in tumoral tissue and lacking activating epdermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) infusions.MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2018-001375-21-PLAstraZeneca AB650
招募中
1 期
A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) following first-line induction therapy with carboplatin, etoposide and atezolizumabSmall-Cell Lung Cancer (SCLC)MedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864CTIS2023-503868-16-00F. Hoffmann-La Roche AG658
进行中（未招募）
3 期
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Early Breast CancerJPRN-jRCT2031210363Tanja Badovinac Crnjevic4,100
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus Everolimus in Patients with Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerEstrogen Receptor (ER)-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer previously treated with a CDK4/6 inhibitor and endocrine therapyMedDRA version: 23.0Level: PTClassification code: 10083232Term: HER2 negative breast cancer Class: 100000004864MedDRA version: 23.0Level: LLTClassification code: 10070575Term: Estrogen receptor positive breast cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10072740Term: Locally advanced breast cancer Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104CTIS2023-506821-12-00Genentech Inc.367